Anavex Life Sciences (AVXL) Q1 2026 earnings summary

Executive summary

• Advanced clinical pipeline focused on oral blarcamesine for early Alzheimer's disease and other CNS disorders, with ongoing and completed clinical trials in Alzheimer's, Parkinson's, Rett syndrome, Fragile X syndrome, and schizophrenia.

• Engaged with regulatory agencies in the US and Europe, including FDA Type C meeting and EMA re-examination request after initial CHMP negative opinion on blarcamesine.

• Participation in ACCESS-AD, a major European initiative to accelerate adoption of innovative Alzheimer's diagnostics and therapeutics, with blarcamesine to be evaluated in a clinical prediction study.

• Completed key clinical trials in Alzheimer's, Parkinson's, Rett syndrome, and schizophrenia, with positive safety and efficacy trends reported.

• Multiple scientific presentations and publications planned, including new biomarker and genetic findings.

Financial highlights

• Cash and cash equivalents were $131.7 million at December 31, 2025, up from $102.6 million at September 30, 2025, with no debt and a projected cash runway exceeding three years.

• Research and development expenses decreased to $4.7 million from $10.4 million year-over-year; general and administrative expenses fell to $2.1 million from $3.1 million.

• Net loss for the quarter was $5.7 million ($0.06 per share), improved from $12.1 million ($0.14 per share) in the prior year.

• Cash used in operating activities was $7.1 million to $7.2 million for the quarter.

• $36.3 million raised through equity financing in Q1 FY2026.

Outlook and guidance

• Expectation to submit existing phase IIB/III data to FDA and continue regulatory engagement for blarcamesine.

• EMA re-examination process for blarcamesine expected to last through the first half of the year, with a 60+60 day review period.

• Plans to initiate or advance new clinical trials in Parkinson's disease, Rett syndrome, Fragile X syndrome, and schizophrenia-related disorders.

• ACCESS-AD trial to serve as a confirmatory study for regulatory purposes.

• Management expects continued negative cash flows from operations as all drug candidates remain in clinical development.